OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 13 BIOGEN 2021 YEAR IN REVIEW Advancing DE&I We believe diversity is a strength and prejudice is unacceptable. Our steadfast commitment to Diversity, Equity & Inclusion (DE&I) starts at the top, and extends throughout our company and to our patients, industry and communities. DE&I goals, progress and reporting Since our last report, we have advanced our DE&I strategy, and were encouraged that through our 2021 ESG materiality assessment, both internal and external stakeholders said they see Biogen’s commitment to DE&I is a core strength. In the past year, we have sustained our focus on hiring and engaging a diverse workforce, promoting health equity and achieving notable gains in supplier diversity. We furthered our commitment to transparency in reporting, sharing the results of a global pay equity analysis with employees, publicly disclosing EEO-1 data that provide a demographic breakdown of our workforce by gender and race, and releasing our first standalone DE&I report in October. Reflecting our broader commitment to these critical issues, we also tied a portion of our employees’ and executive officers’ 2021 compensation to advancing our ESG priorities, which include DE&I goals. OUR FOUR-PART DE&I STRATEGY Build company-wide awareness, capability and urgency to foster and sustain a diverse and inclusive environment. Þ LEARN MORE Promote economic empowerment and expand sourcing with minority-owned businesses. Þ LEARN MORE Build an intentional, high-performing, engaged, diverse and inclusive talent pipeline. Þ LEARN MORE Improve health outcomes for African American, Black, Hispanic, Latino and other underserved communities in the disease areas we treat. Þ LEARN MORE #4 #3 #2 #1 SPOTLIGHT Advancing transparency: Biogen’s first public DE&I Report While DE&I goals and progress are regularly reported in our Year in Review reports, to dive deeper, in 2021, we issued our first-ever, standalone public DE&I Report . During report development, we were awestruck by how many employees volunteered their time and energy , adding to their already full workload to help advance our DE&I strategy and transparency. The report is filled with personal employee stories, bringing to life our people’s passion and drive, and underscoring that DE&I is an ongoing journey – one that requires humility, openness and determination. Strategy and key progress Advancing our DE&I strategy relies on Biogen leadership and a cross- functional governing body of employees known as the DE&I Strategic Council. In 2021, we scaled our DE&I team by adding a dedicated U.S. Partner, a Learning Partner and a hybrid People Relations/DE&I Partner. We also expanded our global focus with the formation of a DE&I Council in the Biogen Intercontinental Region. Both councils work to assure that our talent processes disrupt bias, that everyone across the company owns DE&I, and that our strategy also focuses on serving the needs of underserved and underrepresented patients in the disease areas we treat.